Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 1, 2012, Pages 261-266

  Lakshminarayanan, Vani ^a   Thompson, Pamela ^b   Wolfert, Margreet A ^b   Buskas, Therese ^b   Bradley, Judy M ^c   Pathangey, Latha B ^c   Madsen, Cathy S ^a   Cohen, Peter A ^c   Gendler, Sandra J ^a   Boons, Geert Jan ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Cancer vaccine; Chemical synthesis; Multicomponent; Tn antigen

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER PREVENTION; CARBOHYDRATE ANALYSIS; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; COVALENT BOND; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GLYCOSYLATION; HELPER CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUCIN-1; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; VACCINES, SYNTHETIC;

EID: 84856000561     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115166109     Document Type: Article

References (56)

1. Tarp MA, Clausen H (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780:546-563. (Pubitemid 351381249)
2. Beatson RE, Taylor-Papadimitriou J, Burchell JM (2010) MUC1 immunotherapy. Immunotherapy 2:305-327.
3. Hanisch FG, Ninkovic T (2006) Immunology of O-glycosylated proteins: Approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr Protein Pept Sci 7:307-315.
4. Ju T, Cummings RD (2002) A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA 99:16613-16618. (Pubitemid 36034021)
5. Cheever MA, et al. (2009) The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337.
6. von Mensdorff-Pouilly S, et al. (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574-583.
7. Blixt O, et al. (2011) Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 13:R25.
8. von Mensdorff-Pouilly S, et al. (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86:702-712.
9. Graves CR, Robertson JF, Murray A, Price MR, Chapman CJ (2005) Malignancy-induced autoimmunity to MUC1: Initial antibody characterization. J Pept Res 66:357-363. (Pubitemid 41784383)
10. Coltart DM, et al. (2002) Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. J Am Chem Soc 124:9833-9844.
11. Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S (2004) Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 14:681-692. (Pubitemid 39161975)
12. Dziadek S, Griesinger C, Kunz H, Reinscheid UM (2006) Synthesis and structural model of an alpha(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions. Chemistry 12:4981-4993. (Pubitemid 43999118)
13. Doménech N, Henderson RA, Finn OJ (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155:4766-4774.
14. Haurum JS, et al. (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190:145-150. (Pubitemid 29330132)
15. Vlad AM, et al. (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196:1435-1446. (Pubitemid 35424938)
16. Stepensky D, Tzehoval E, Vadai E, Eisenbach L (2006) O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 143:139-149.
17. Ninkovic T, Hanisch FG (2007) O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 179:2380-2388.
18. Brossart P, et al. (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317. (Pubitemid 29279274)
19. Ninkovic T, et al. (2009) Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 47:131-140.
20. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT (1996) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304. (Pubitemid 26197209)
21. Karanikas V, et al. (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783-2792. (Pubitemid 28007547)
22. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58:315-321. (Pubitemid 28047073)
23. Adluri S, et al. (1999) Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer 79:1806-1812. (Pubitemid 29132309)
24. Acres B, et al. (2000) MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48:588-594. (Pubitemid 30004493)
25. Gilewski T, et al. (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693-1701. (Pubitemid 30305061)
26. Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555-6563. (Pubitemid 32467194)
27. Butts C, et al. (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674-6681. (Pubitemid 46190262)
28. Longenecker BM, Reddish M, Koganty R, MacLean GD (1994) Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis. Adv Exp Med Biol 353:105-124. (Pubitemid 24256919)
29. Ragupathi G, et al. (1999) Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol Immunother 48:1-8. (Pubitemid 29197237)
30. Kagan E, et al. (2005) Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol Immunother 54:424-430. (Pubitemid 40543682)
31. Julien S, et al. (2009) Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 100:1746-1754.
32. Sørensen AL, et al. (2006) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16:96-107. (Pubitemid 43125966)
33. Xu Y, Gendler SJ, Franco A (2004) Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 199:707-716. (Pubitemid 38316437)
34. Mukherjee P, et al. (2007) MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 25:1607-1618. (Pubitemid 46108207)
35. Mukherjee P, et al. (2003) Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26:47-62. (Pubitemid 36056825)
36. Leclerc C, Deriaud E, Mimic V, van der Werf S (1991) Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1. J Virol 65:711-718.
37. Spohn R, et al. (2004) Synthetic lipopeptide adjuvants and Toll-like receptor 2 - structure-activity relationships. Vaccine 22:2494-2499. (Pubitemid 38757349)
38. Apostolopoulos V, et al. (2003) A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 100:15029-15034. (Pubitemid 37518011)
39. Ingale S, Buskas T, Boons GJ (2006) Synthesis of glyco(lipo)peptides by liposomemediated native chemical ligation. Org Lett 8:5785-5788.
40. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680. (Pubitemid 32747155)
41. Van Amersfoort ES, Van Berkel TJC, Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379-414. (Pubitemid 36871313)
42. Cohen PA, et al. (2008) STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 112:1832-1843.
43. Hirotani T, et al. (2005) Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-beta. Biochem Biophys Res Commun 328:383-392. (Pubitemid 40208323)
44. Morse MA, Whelan M (2010) A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther 12:11-13.
45. Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ (2007) Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol 3:663-667. (Pubitemid 47417705)
46. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9:57-63.
47. Zhang Y, et al. (2011) TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol 186:1963-1969.
48. Keler T, Ramakrishna V, Fanger MW (2004) Mannose receptor-targeted vaccines. Expert Opin Biol Ther 4:1953-1962. (Pubitemid 39627146)
49. Tacken PJ, Torensma R, Figdor CG (2006) Targeting antigens to dendritic cells in vivo. Immunobiology 211:599-608.
50. Braun P, et al. (1998) Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1. Bioorg Med Chem 6:1531-1545. (Pubitemid 28446232)
51. Deck MB, Sjölin P, Unanue ER, Kihlberg J (1999) MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. J Immunol 162:4740-4744. (Pubitemid 29314875)
52. Bäcklund J, et al. (2002) Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 99:9960-9965. (Pubitemid 34831155)
53. Buskas T, Li YH, Boons GJ (2004) The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry 10:3517-3524.
54. Inaba K, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702.
55. Mukherjee P, et al. (2001) MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 18:931-942. (Pubitemid 36315058)
56. Gaekwad J, et al. (2010) Differential induction of innate immune responses by synthetic lipid a derivatives. J Biol Chem 285:29375-29386.